SCHEMBL4016472

SCHEMBL4016472

CNc1cccc(-c2ccc3nonc3c2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDO2 P48775 1/20 0.40
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
HPGD P15428 1/20 0.39
CYP2C19 P33261 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ENPP2 Q13822 2/20 0.39
PIK3CD O00329 1/20 0.39
TLR8 Q9NR97 1/20 0.38
TLR7 Q9NYK1 1/20 0.38
MAPT P10636 2/20 0.38
FABP3 P05413 1/20 0.37
FABP4 P15090 1/20 0.37
FABP5 Q01469 1/20 0.37
NTRK1 P04629 1/20 0.36
BRD4 O60885 1/20 0.36
TRIM58 Q8NG06 1/20 0.36
MAP4K4 O95819 2/20 0.35
NPC1 O15118 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4016183 0.84 ENPP2 (0.42) TDO2ENPP2PIK3CDMAPTNPC1
SCHEMBL4649312 0.80 NPC1 (0.49) TDO2ENPP2MAPTNPC1POLB
SCHEMBL28488286 0.78 TSHR (0.48) CYP3A4MAPTNTRK1BRD4PLK1
SCHEMBL3078778 0.78 ENPP2 (0.58) TDO2ENPP2PIK3CDFABP3FABP4
SCHEMBL4015871 0.76 KMT2A (0.41) NTRK1BRD4NPC1POLB
SCHEMBL4014202 0.76 ENPP2 (0.43) TDO2ENPP2PIK3CDMAPTFABP4
SCHEMBL4022329 0.74 ENPP2 (0.62) CYP1A2CYP3A4CYP2D6CYP2C19ENPP2
SCHEMBL980630 0.74 MAP4K4 (0.50) TDO2CYP3A4HPGDSMN1; SMN2ENPP2
SCHEMBL4015933 0.73 NOTUM (0.46) TDO2SMN1; SMN2ENPP2TLR8TLR7
SCHEMBL4014543 0.73 NPC1 (0.42) TDO2CYP1A2CYP3A4CYP2D6HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7632851-B2 Benzo[1,2,5]oxadiazoles and benzol[1,2,5]thiadiazoles useful as histopathological staining agents, imaging agents and biomarkers NOVARTIS AG (CH) 2009-12-15 US disclosed
EP-1613610-B1 BENZO 1,2,5 OXADIAZOLES AND BENZO 1,2,5 THIADIAZOLES USEFUL AS HISTOPATHOLOGICAL STAINING AGENTS, IMAGING AGENTS AND BIOMARKERS NOVARTIS AG (CH) 2009-07-01 EP disclosed
US-20060093551-A1 Benzo[1,2,5]oxadiazoles and benzol[1,2,5]thiadiazoles useful as histopathological staining agents, imaging agents and biomarkers NOVARTIS AG (CH) 2006-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060093551-A1 Benzo[1,2,5]oxadiazoles and benzol[1,2,5]thiadiazoles useful as histopathological staining agents, imaging agents and biomarkers H1-3, MKI67, H1-5 TDO2 1336/4885CYP1A2 933/4885CYP3A4 1408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.